摘要
TP53突变是表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)最常见的合并体突变,在靶向治疗过程中与疾病进展和较差的预后相关。为揭示TP53突变在EGFR突变的晚期NSCLC靶向治疗中的预后价值,探讨治疗方案,国内外医学界进行了深入的研究,但尚未达成共识。全文就近年来EGFR/TP53共突变的NSCLC靶向治疗的进展进行综述,为临床治疗研究提供新思路。
Concomitant mutation of TP53 and EGFR is common,which is generally believed to be related to disease progression and poor prognosis in target therapy for EGFR driven non-small cell lung cancer(NSCLC).Studies have revealed the predictive value of TP53 mutation in the treatment of EGFR driven advanced NSCLC,though there is no consensus yet.This review summarizes the development of treatment for advanced NSCLC with concurrent EGFR and TP53 mutations,to provide novel ideas for further researches.
作者
李继先
冯阿磊
戴洪海
杨哲
LI Ji-xian;FENG A-lei;DAI Hong-hai;YANG Zhe(Shandong University,Jinan 250021,China;Shandong Provincial Hospital,Jinan 250021,China)
出处
《中国肿瘤》
CAS
CSCD
北大核心
2022年第9期753-758,共6页
China Cancer
基金
希思科-领航肿瘤研究基金(Y2019AZM-0522)
蕙兰公益-豪森药业肺癌精准医学研究专项基金(HL-HS2020-73)。
关键词
非小细胞肺癌
EGFR突变
TP53突变
靶向治疗
血管生成抑制剂
non-small cell lung cancer
epidermal growth factor receptor mutation
TP53 mutation
targeted therapy
angiogenesis inhibitor
